Text Size: A- A+ Facebook Twitter LinkedIn YouTube

Breaking News

Pledge the Gift of Life

Each year, the lives of thousands of people across the country are saved because someone made the choice to become an organ donor. In April, Allegheny Health Network is honored to celebrate National Donate Life Month and pay tribute to all of those who have bestowed the precious gift of life to another through organ donation. Visit AHNdonate.org to learn more and register to be an organ donor.



Format: 04/19/2014
Format: 04/19/2014


Pittsburgh Tribune-Review: Cancer 'wonder drug' might not be effective in early stages

Tuesday, June 2nd, 2009

By Allison M. Heinrichs


A "wonder" drug that fights breast, lung and colon cancer by cutting off blood supply to tumors doesn't seem to pack the same punch in colon cancer caught early, according to research from Allegheny General Hospital presented Saturday at a national cancer conference in Florida.

Avastin, made by pharmaceutical giant Roche's Genentech unit, did not improve the three-year survival rate in patients with early stages of colon cancer when compared with patients receiving standard chemotherapy, scientists said at the annual meeting of the American Society of Clinical Oncology in Orlando.

"It's been approved for advanced cancer, and it was hoped that moving it into early stage colon cancer would increase the rate of cures," said Allegheny General oncologist Dr. Norman Wolmark, lead researcher on the study. "And it didn't."

Through the National Surgical Adjuvant Breast and Bowel Project, based at Allegheny General, doctors at more than 250 hospitals worldwide recruited 2,710 early-stage colon cancer patients. Half were treated with one year of Avastin and chemotherapy; half received just chemotherapy.

Avastin is known by the generic name bevacizumab. Potential side effects include development of a hole in the stomach and bleeding problems that can hamper wound healing. Few patients experienced side effects in the clinical trial, with high blood pressure being the major problem, Wolmark said. Genentech helped pay for the clinical trial, as did the National Cancer Institute.

Though both groups of patients ultimately had the same outcome — about 75 percent lived three years without recurrence of cancer — patients on Avastin had 40 percent fewer cancer recurrences during the year they took the drug.

"While it was being given, it was effective," Wolmark said. "But after it was discontinued, the benefit disappeared, raising the extremely important question whether giving it over a longer period of time would increase the benefit."

To read more, visit the Tribune-Review web site.


West Penn Allegheny Health System
Tell us who you are:

What areas do you use on our website?*
(select more than one if it applies)

Did you find what you were looking for?

Would you refer others to our website?

Can we contact you for future questions?

CAPTCHA math question:* 3 + 4 =

Thank you for completing the West Penn Allegheny Health System website survey.
We value your feedback and comments.